

## LEGAL NOTICE

### **XARELTO QUEBEC CLASS ACTION SETTLEMENT APPROVAL HEARING**

A Canada-wide settlement has been reached in a class action relating to the prescription drug Xarelto®. On July 22, 2020, the Superior Court of Quebec authorized a class action in the judicial district of Montreal in the case of *Gagnon vs. Bayer Inc. et al.*, court file no. 500-06-000732-152. A similar class action was certified in the Court of King's Bench for Saskatchewan for residents of Canada outside of Quebec.

A Canada-wide settlement has been reached to settle the Quebec and Saskatchewan class actions. A court hearing that you may attend will be held in Montreal on **May 19, 2026 at 9:15 A.M.** in room 17.09 at the Montrel Courthouse (1 Notre-Dame Street East, Montreal, Quebec, H2Y 1B6) to request court approval of the settlement agreement by the Quebec court. If the settlement is approved by courts in both provinces, it will bind all Canadians wherever they reside, and all Canadian class proceedings will come to an end. If the settlement is not approved, the class action will continue and you will be bound by the result unless you opt out as described below.

#### **WHAT IS THE CLASS ACTION ABOUT?**

The class action alleges that class members experienced bleeding-related injuries that were allegedly related to the use of Xarelto®. Bayer denies the allegations and they have not been proven in court.

#### **AM I A CLASS MEMBER?**

You are a class member in the Quebec class action if you are a Quebec resident who was prescribed and ingested Xarelto® (rivaroxaban) from January 1, 2008 to October 27, 2025, or are a successors, assigns, family members, and dependants. See [www.mnp.ca/xarelto/settlement](http://www.mnp.ca/xarelto/settlement) for a complete list of family members who may make a claim under the settlement.

#### **WHAT CAN CLASS MEMBERS RECEIVE UNDER THE SETTLEMENT?**

If the settlement is approved, a settlement fund of between \$4,500,000 and \$5,250,000 will be created based on the number of claims that are approved. The fund will be used to compensate individuals who establish with supporting documentation that they experienced specified bleeding events within a specified period of time after using Xarelto®, specified family members of such individuals, the provincial and territorial governments who paid healthcare costs on their behalf, expenses to administer the settlement, and legal fees and disbursements and applicable taxes. Details of how and when claim forms must be submitted to be eligible for compensation will be provided by a separate Court-approved notice if the Settlement is approved. You should visit the website listed below to ensure that you do not miss the deadline to submit a claim for compensation.

## CAN I OPT OUT OF THE CLASS ACTION?

If you are a member of the Quebec Class and wish to participate in the Settlement, you do not need to do anything at this time. If you are a member of the Quebec Class who was prescribed and has ingested Xarelto® prior to October 1, 2020, you may not opt out of this class action.

If you are a member of the Quebec Class who was prescribed and has ingested Xarelto® between October 1, 2020 and October 27, 2025 and if you do not wish to participate in the Settlement, then you must opt out of this class action. In that case, you must send an opt out form by no later than **March 10, 2026** to the Claims Administrator and to the registry of the Superior Court of Quebec, District of Montreal, at 1 Notre-Dame Street East, Montreal, Quebec, H2Y 1B6.

If you wish to remain in the class action but object to the fairness of the settlement or any of its terms, you may alternatively send an objection and notice of intention to appear by no later than **March 10, 2026** to MNP Ltd. at the address listed below.

## LEGAL REPRESENTATION

CONSUMER LAW GROUP INC.  
1030 Berri St., Suite 102  
Montreal (Quebec) H2L 4C3  
Jeff Orenstein  
Tel: (514) 266-7863 ext. 2  
Fax: (514) 868-9690  
[jorenstein@clg.org](mailto:jorenstein@clg.org)

## TO LEARN MORE ABOUT THIS CLASS ACTION

You can review the full notice of settlement approval hearing and additional documents related to the class action, including the originating documents, the authorization judgement, and the settlement agreement at the settlement website: [www.mnp.ca/xareltosettlement](http://www.mnp.ca/xareltosettlement), or you can contact the court-appointed claims administrator at

MNP LTD.  
Suite 2000, 112 – 4th Avenue SW  
Calgary (Alberta) T2P 0H3  
Tel: (877) 500-0792  
Fax: (403) 537-8437  
[xareltosettlement@mnp.ca](mailto:xareltosettlement@mnp.ca)

*This notice is not a solicitation by a lawyer. The content of this abbreviated notice and the full notice that is available at [www.mnp.ca/xareltosettlement](http://www.mnp.ca/xareltosettlement), has been approved by the Superior Court of Quebec. Please direct any inquiries about the class action to either firm listed above and not to the court nor to Bayer.*